Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions

Core Insights - Illumina and Broad Clinical Labs are collaborating to develop a 5 billion single-cell atlas within three years, setting a new standard for scalable single-cell research [1][2][3] - The partnership aims to enhance understanding of biology and disease through advanced single-cell sequencing technologies [3][4] - The integration of Illumina's technologies with Broad's expertise will facilitate high-throughput processing of single-cell samples, enabling significant advancements in precision health [4][5] Company Overview - Illumina is a leader in next-generation sequencing and array-based technologies, focusing on improving human health through genomic insights [8] - Broad Clinical Labs, a non-profit subsidiary of the Broad Institute, specializes in translational genomics and has sequenced over 700,000 genomes to enhance disease understanding and diagnosis [7][8] Technological Advancements - The collaboration will utilize cutting-edge tools such as Perturb-seq and Illumina's Single Cell 3' RNA Prep, allowing for rapid and consistent data generation [4][5] - The combination of Illumina's NovaSeq™ X Plus platform and DRAGEN™ analysis software will create a seamless workflow for processing single-cell samples [4]